オオモリ　テツペイ   Oomori Tetsupei   大森　鉄平    所属   医学部 医学科（東京女子医科大学病院）    職種   非常勤講師
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Efficacy and safety of tacrolimus in older adults with ulcerative colitis: a retrospective study
掲載誌名	正式名：BMC gastroenterology 略　 称：BMC Gastroenterol ISSNコード：1471230X/1471230X
掲載区分	国外
巻・号・頁	24(1),pp.22
著者・共著者	ITO Ayumi, MURASUGI Shun, OMORI Teppei, NAKAMURA Shinichi, TOKUSHIGE Katsutoshi
発行年月	2024/01
概要	BACKGROUND/AIMS:The prevalence of ulcerative colitis (UC) has been increasing, also in older adults. Here, we retrospectively compared the efficacy and safety of tacrolimus (TAC) in older and younger patients with UC.METHODS:We included younger (age < 65 years; n = 116) and older patients (age ≥ 65 years; n = 21) with UC who received TAC from April 2009 through December 2022(mean follow-up, 1230 ± 175 days) and achieved remission. Evaluations included age at onset, laboratory values, estimated glomerular filtration rate (eGFR), use of 5-aminosalicylic acid (5-ASA), biological experience, colonoscopy scores, remission at 1 month after treatment initiation, and adverse events. Treatment duration and renal function were assessed in patients with follow-up data (younger patients, n = 110; older patients, n = 19).RESULTS:Older patients had a higher age at onset and treatment initiation but less 5-ASA use and biological experience. Before treatment, hemoglobin, albumin, and eGFR were significantly lower in the older group and CRP was significantly higher. The remission rate was 80.1% in the younger group and 66.6% in the older group (P = 0.1862). Adverse events were similar in both groups. The older group had a shorter treatment duration and significantly less change in renal function at all time points.DISCUSSION:Rates of TAC-induced remission and adverse events were similar in older and younger adults with UC.CONCLUSION:TAC can be used safely in elderly patients with moderate to severe UC with careful monitoring.
DOI	10.1186/s12876-023-03089-4
PMID	38191328